# VEGA DAILY

Unlock Your Best Quote Ask VEGA Now!

### **November 12, 2025**

#### VITAMIN

01

Vitamin E prices in Europe continue to climb, now matching or even exceeding China's export levels—a clear sign of strong global demand and tightening supply. With most producers' orders booked through year-end, spot availability remains limited as buyers begin securing Q1 2026 stocks in advance. While new capacity developments are underway, the global supply-demand balance will likely remain tight in the near term.

## AMINO ACID

02

According to Russian media, the Donbiotech plant in the Rostov region is expected to begin commercial production of L-lysine hydrochloride in the second half of 2027. The facility will initially process 250,000 tons of grain annually to produce 40,500 tons of L-lysine HCl—a product that Russia currently imports entirely. In its second phase, the project plans to add tryptophan, valine, and threonine production, with operations scheduled to start in 2028 or later. The total investment is estimated at 34.6 billion rubles (about USD 425 million). Construction originally began in 2010 but was suspended in 2018 due to financial issues.

API 03

On November 10, Fushilai held its 5th Board Meeting and approved a proposal to extend the completion date of its "289-ton specialty API expansion project" to December 31, 2026. Meanwhile, Hisun Pharmaceutical announced on November 11 that it has submitted a listing application to the Taizhou Property Rights Exchange for the transfer of 100% equity in its wholly owned subsidiary, Zhejiang Pharmaceutical Industry Co., Ltd. The listing period runs from November 11 to December 8, 2025.

## FOOD ADDITIVE

04

Recently, when Kingdomway responded to the inquiries of researchers, they stating that its Doctor's Best brand in China covers multiple segments, including cardiovascular health, anti-aging, bone strength, and essential vitamins. Among its offerings, Coenzyme Q10, ergothioneine, NAD+, magnesium, vitamin K, and vitamin D products remain the most popular. Doctor's Best has continued to see steady growth in both revenue and profit during the first three quarters of 2025.

Reported by Candice, Shea and Sharon

ONE STOP SOLUTION SUPPLIER







